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A B S T R A C T
Purpose
To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) –positive primary
breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level
was. 10%after 2 to 4weeks of neoadjuvant aromatase inhibitor (AI) therapy. A second objectivewas
to examine risk of relapse using the Ki67-based Preoperative Endocrine Prognostic Index (PEPI).
Methods
The American College of Surgeons Oncology Group (ACOSOG) Z1031A trial enrolled post-
menopausal women with stage II or III ER-positive (Allred score, 6 to 8) breast cancer whose
treatment was randomly assigned to neoadjuvant AI therapy with anastrozole, exemestane, or
letrozole. For the trial ACOSOG Z1031B, the protocol was amended to include a tumor Ki67 de-
termination after 2 to 4 weeks of AI. If the Ki67 was. 10%, patients were switched to neoadjuvant
chemotherapy. A pCR rate of . 20% was the predefined efficacy threshold. In patients who
completed neoadjuvant AI, stratified Cox modeling was used to assess whether time to recurrence
differed by PEPI = 0 score (T1 or T2, N0, Ki67 , 2.7%, ER Allred . 2) versus PEPI . 0 disease.
Results
Only two of the 35 patients in ACOSOG Z1031B who were switched to neoadjuvant chemotherapy
experienced a pCR (5.7%; 95%CI, 0.7% to 19.1%). After 5.5 years of median follow-up, four (3.7%)
of the 109 patients with a PEPI = 0 score relapsed versus 49 (14.4%) of 341 of patients with PEPI. 0
(recurrence hazard ratio [PEPI = 0 v PEPI . 0], 0.27; P = .014; 95% CI, 0.092 to 0.764).
Conclusion
Chemotherapy efficacy was lower than expected in ER-positive tumors exhibiting AI-resistant
proliferation. The optimal therapy for these patients should be further investigated. For patients with
PEPI = 0 disease, the relapse risk over 5 years was only 3.6%without chemotherapy, supporting the
study of adjuvant endocrine monotherapy in this group. These Ki67 and PEPI triage approaches are
being definitively studied in the ALTERNATE trial (Alternate Approaches for Clinical Stage II or III
Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment in Postmenopausal Women: A
Phase III Study; clinical trial information: NCT01953588).
J Clin Oncol 35:1061-1069. © 2017 by American Society of Clinical Oncology. Creative Commons
Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-
nc-nd/4.0/
INTRODUCTION
For postmenopausal women with clinical stage II
or III estrogen receptor (ER) –positive breast
cancer, neoadjuvant aromatase inhibition (AI) is
an underused and low-toxicity alternative to
chemotherapy for increasing breast conservation
rates.1 A barrier to greater adoption of neo-
adjuvant AI is high response variability. We
therefore postulated that an early switch from
AI to neoadjuvant chemotherapy could produce
Author affiliations and support information
(if applicable) appear at the end of this
article.
Published at jco.org on January 3, 2017.
M.J.E. and V.J.S. are joint first authors.
The content is solely the responsibility of
the authors and does not necessarily
represent the official views of the National
Institutes of Health or the companies
involved.
Clinical trial information: NCT00265759.
Corresponding author: Matthew J. Ellis,
MB, BChir, PhD, Lester and Sue Smith
Breast Center, One Baylor Plaza,
MSBCM600, Houston, TX 77030; e-mail:
mjellis@bcm.edu.
© 2017 by American Society of Clinical
Oncology. Creative Commons Attribution
Non-Commercial No Derivatives 4.0
License.
0732-183X/17/3510w-1061w/$20.00
ASSOCIATED CONTENT
See accompanying Editorial
on page 1031
Appendix
DOI: 10.1200/JCO.2016.69.4406
Data Supplements
DOI: 10.1200/JCO.2016.69.4406
DOI: 10.1200/JCO.2016.69.4406
© 2017 by American Society of Clinical Oncology 1061
VOLUME 35 • NUMBER 10 • APRIL 1, 2017
better clinical outcomes for tumors that responded poorly to AI.
Conversely, adjuvant AI alone may be sufficient to prevent relapse
in tumors highly responsive to neoadjuvant AI.
Pathologic complete response (pCR) after systemic chemo-
therapy remains a controversial clinical trial end point,2,3 and al-
ternatives are needed, particularly in ER-positive, human epidermal
growth factor receptor 2–negative disease (HER2-negative), where
pCR rates are low. Data from a neoadjuvant study comparing
letrozole and tamoxifen in postmenopausal womenwith ER-positive
breast cancer—P024 (Preoperative Treatment of Postmenopausal
Breast Cancer Patients with Letrozole: A Randomized Double-
Blind Multicenter Study)4-6—was previously used to generate the
Preoperative Endocrine Prognostic Index (PEPI).7 PEPI requires
pathologic stage (tumor size and nodal status), in addition to levels
of the protein encoded by the MKI67 gene (Ki67), and Allred ER
score measured on the surgical specimen (with surgery conducted
during uninterrupted endocrine therapy). Patients with a PEPI score
of 0 (pT1 or pT2, pN0, Ki67 # 2.7%, Allred score . 2) from the
P024 trial were found to have a low risk of relapse. Similar findings
were observed in the neoadjuvant IMPACT trial (Immediate Pre-
operative Anastrozole, Tamoxifen, or Combined with Tamoxifen)2,
but no subsequent validation efforts have been reported.
The American College of Surgeons Oncology Group (ACO-
SOG) Z1031A randomized phase II clinical trial was designed to
determine which AI (anastrozole, letrozole, or exemestane) should
be recommended for future testing against chemotherapy in the
neoadjuvant setting (ACOSOG is now a part of the Alliance for
Clinical Trials in Oncology). The major initial finding from
ACOSOG Z1031A was that half of the patients who were con-
sidered candidates for mastectomy or inoperable before neo-
adjuvant AI therapy had successful breast-conserving surgery.8
When the enrollment in ACOSOG Z1031A was complete, an
amendment was introduced (ACOSOG Z1031B) that triaged
patients with tumors exhibiting a Ki67. 10% in a tumor biopsy 2
to 4 weeks after starting AI to standard chemotherapy. The hy-
pothesis being tested was that the pCR rate would be at least 20% in
this AI-resistant population. Herein, we report the pCR results
from ACOSOG Z1031B as well as the time to recurrence by PEPI
status among all ACOSOG Z1031 patients who completed neo-
adjuvant AI treatment.
METHODS
Establishment of an Early Ki67 Cut Point for Triage to
Chemotherapy
An on-treatment Ki67 threshold for switching from neoadjuvant AI
therapy to neoadjuvant chemotherapy was established using data from the
Preoperative Letrozole study (POL)9 and the IMPACT trial.10 A Ki67 value
of . 10% at 1 month in the POL study was associated with a higher PEPI
score (P = .01), a smaller number of patients in the PEPI-0 group (P = .08),
and worse relapse-free survival (P = .0016). Similarly, the IMPACT data
confirmed that a 2-week Ki67 . 10% predicted a higher PEPI score
(P = .001), smaller numbers of patients in the PEPI-0 group (P = .004), and
worse relapse-free survival (P = .008; Data Supplement; Appendix Table A1
and Figure A1A, online only). Combining these studies revealed only one
PEPI-0 case among 51 patients with a 2- to 4-week Ki67 value of . 10%.
Thus, according to the PEPI model, patients with a Ki67 value of 10% at 2
to 4 weeks had a , 2% chance of a favorable PEPI score that would allow
them to safely avoid chemotherapy under current guidelines.
Patient Eligibility
Eligible patients were postmenopausal with invasive breast cancer
(clinical stage T2 to T4c, N0 to N3, M0). Additional criteria have been
previously described.8 This study was supported by the Clinical Trials
Support Unit and approved by the institutional review boards of all
participating institutions. Each participant signed an institutional review
board–approved, protocol-specific informed consent in accordance with
federal and institutional guidelines.
Treatment Schema
Patients enrolled in ACOSOG Z1031B underwent a core breast bi-
opsy for Ki67 determination after 2 weeks of AI therapy. If the Ki67 was
# 10%, the patient continued AI therapy for another 12 to 14 weeks and
then proceeded to surgery. Women whose 2-week Ki67 level was . 10%
were offered either a National Comprehensive Cancer Network–approved
neoadjuvant chemotherapy regimen or surgery at the discretion of their
providers and/or the patients. If the biopsy core contained insufficient
tumor to perform the Ki67 assay, patients could elect to undergo a repeat
biopsy at 4 weeks or continue on AI therapy. If severe treatment-related
toxicity was reported or the patient refused further AI therapy, surgery
was recommended. Within 14 days of registration, patients underwent
a complete physical examination with tumor assessment. Every 4 weeks,
patients underwent a physical examination, toxicity assessment, and tumor
assessment using February 2000 WHO criteria. If tumor progression was
suspected, ultrasound or mammogram was required, and neoadjuvant AI
was discontinued if progression was confirmed. Blood and biopsy spec-
imens for correlative studies were collected at baseline, 2 to 4 weeks after
the start of neoadjuvant AI treatment, on discontinuation of neoadjuvant
treatment, and at surgery. For patients with PEPI = 0 disease, management
without chemotherapy was recommended but not mandatory to de-
termine the acceptability of this recommendation.
AI Treatment
Before the release of the ACOSOG Z1031A results,8 eligible patients
were randomly assigned to 16 to 18 weeks of neoadjuvant AI with
exemestane 25 mg once daily, letrozole 2.5 mg once daily, or anastrozole
1 mg once daily. After the release of the data, patients could choose either
letrozole or anastrozole treatment.
Statistical Considerations
The primary end point for ACOSOG Z1031B was the pCR rate
among the women who after 2 weeks of neoadjuvant AI therapy had
a tumor Ki67 level of . 10% and switched to neoadjuvant chemotherapy.
pCR was defined as histologic evidence of no invasive tumor cells in the
surgical breast specimen or ipsilateral lymph nodes. A one-stage phase II
clinical trial design was chosen to assess the pCR rate. With a sample size of
35 and a one-sided a = 0.10, a one-sample binomial test of proportions
would have a 90% chance of declaring success with a pCR rate of at least
20% compared with the null hypothesis that the pCR was 5% (at least four
pCRs were needed to conclude pCR rate $ 20%). A 90% binomial
confidence interval for the true pCR was also constructed. On the basis of
the IMPACTstudy, it was estimated that 235 eligible womenwould need to
enroll to obtain 35 women with a 2-week Ki67. 10% willing to switch to
neoadjuvant chemotherapy. The long-term PEPI outcome study cohort
excluded women from both ACOSOG Z1031A and Z1031B who withdrew
consent not having started neoadjuvant AI, had metastases or bilateral
invasive breast cancer at registration, failed to undergo surgery, had al-
ternative therapy before surgery, had radiographic confirmed disease
progression or new primary disease during neoadjuvant AI, failed to have
sentinel lymph node or axillary lymph node dissection, or lacked sufficient
tissue to obtain a Ki67 or Allred score. In addition, ACOSOG Z1031B
patients with 2- or 4-week Ki67 . 10% who remained on AI were ex-
cluded. Time to breast cancer recurrence (TBCR) was defined as the time
from surgery to first local, regional, or distant disease recurrence. Patients
1062 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
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without documented disease recurrence were censored at the date of their
last disease evaluation. TBCR was estimated using the Kaplan-Meier
method11 Stratified Cox modeling (with cohort and adjuvant chemo-
therapy use as strata) was used to assess whether TBCR differed with
respect to PEPI 0 status.12 The Alliance Statistics and Data Center
conducted data collection and statistical analyses. Data were locked
on January 11, 2016.
Ki-67 CLIA Assay for ACOSOG Z1031A and Z1031B
For both ACOSOG Z1031 cohorts, a Ki67 clinical trial assay was
performed at the College of American Pathologists– and the Clinical
Laboratory Improvement Amendments–certified Washington University
anatomic and molecular pathology laboratory using the CONFIRM anti-
Ki67 (30-9) rabbit monoclonal primary antibody as a prediluted reagent
on a Benchmark XT platform according to the manufacturer instructions
(Ventana, Tucson, AZ). Tonsil was used as the assay positive control.
Ki-67 Quantification Approaches
A single experienced pathologist (D.C.A.) conducted the real-time
Ki67 scoring for ACOSOG Z1031B. If the estimated rate was low (, 2.7%),
or high (. 10%), a whole slide estimate was conducted. If the score was
between 2.7% and 10%, point counting was conducted using an ocular
grid, at least three high-power fields with a minimum of 100 cells scored.
Retrospective analysis of ACOSOG Z1031A used the iScan Coreo scanner
(Ventana) with the Companion Algorithm Ki-67 (30-9) software. The
imaging approach required three to 10 areas of interest be selected at 43
magnification excluding ductal carcinoma in situ, vessels, and lymphocytes
and avoiding perinecrotic or necrotic areas. The image analysis result was
reviewed to ensure the software was correctly differentiating between benign
andmalignant cells, and, if not, the case was triaged to visual point counting.
The visual point counting approach required color photomicrographs with
a background grid taken at 403 of at least three fields selected based on
invasive tumor content and the quality of the histology, not on Ki67 staining
pattern, to obtain tumor cell count of at least 200. The scorer counted the
total number of tumor cells and the number of Ki67-positive cells that
intersected with first grid line and every third gridline thereafter.
Gene Expression Analysis to Study Cell Cycle–Regulated
Genes
RNA preparation and Agilent 44K gene array analysis(Agilent
Technologies, Santa Clara, CA) approaches were carried out as previously
described.2 The microarray contained probes for 720 of the 874 genes
previously identified as having periodic expression in the cell division cycle
of HeLa cells (Data Supplement).13 Gene expression levels in each tumor
were normalized to the number of standard deviations from the median
expression value across all the tumors. A multigene proliferation score
Table 1. Patient and Disease Characteristics for the ACOSOG Z1031B Cohort Sorted by Early on-Treatment Ki67 Categories
Characteristic Week-2 Ki67 # 10% (n = 165) Week-2 Ki67 . 10% (n = 49)
Week-2 Biopsy, No Invasive
Disease Present (n = 22)
Median age, years (IQR) 65 (58-72) 60 (55-64) 66 (58-72)
Histology
Ductal 114 (69.1) 40 (81.6) 16 (72.7)
Lobular 34 (20.6) 7 (14.3) 4 (18.2)
Mixed ductal/lobular 10 (6.1) 2 (4.1) 0
Other 7 (4.2) 0 2 (9.1)
Grade
1 54 (32.7) 13 (26.5) 8 (36.4)
2 96 (58.2) 22 (44.9) 12 (54.5)
3 15 (9.1) 14 (28.6) 2 (9.1)
HER2 positive 3 (1.8) 2 (4.1) 1 (4.5)
cTstage
T2 131 (79.4) 32 (65.3) 19 (86.4)
T3 27 (16.4) 16 (32.6) 2 (9.1)
T4A-C 7 (4.2) 1 (2.1) 1 (4.5)
cNstage
N0 113 (68.5) 27 (55.1) 21 (95.5)
N1 46 (27.9) 19 (38.8) 1 (4.5)
N2 4 (2.4) 3 (6.1) 0
N3 1 (0.6) 0 0
Unknown 1 (0.6) 0 0
Neoadjuvant endocrine therapy
Anastrozole 72 (43.6) 16 (32.7) 2 (9.1)
Exemestane 21 (12.7) 10 (20.4) 10 (45.4)
Letrozole 72 (43.6) 23 (46.9) 10 (45.4)
Week 2 Ki67 value
0-2.5 89 (53.9) 0
2.6-5.0 44 (26.7) 0
5.1-7.5 20 (12.1) 0
7.6-10.0 12 (7.3) 0
10.1-15.0 0 19 (38.8)
15.1-20.0 0 12 (24.5)
20.1-25.0 0 6 (12.2)
25.1-50.0 0 8 (16.3)
50.1-75.0 0 1 (2.0)
75.1-100 0 3 (6.1)
NOTE. Data presented as No. (%) unless otherwise noted.
Abbreviations: HER2, human epidermal growth factor receptor 2; IQR, interquartile range; Ki67, protein encoded by the MKI67 gene.
jco.org © 2017 by American Society of Clinical Oncology 1063
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(MGPS) for a tumor was the average normalized expression of the 772
genes for that tumor analysis.14 The microarray data sets have been
submitted to Gene Expression Omnibus (GSE87411).
RESULTS
ACOSOG Z1031B Patient Cohort
From October 1, 2009 to November 15, 2011, 245 patients were
enrolled into ACOSOG Z1031B. At week 2, 165 women (69.9%) had
a Ki67 value of# 10%; 49 women (20.8%) had a Ki67 value. 10%,
and 22 women (9.3%) had insufficient tumor to make a Ki67 de-
termination. Patient and disease characteristics of these 236 women
are presented in Table 1 and the CONSORT diagram in Figure 1.
Neoadjuvant Chemotherapy Efficacy for ER-Positive
Tumors Exhibiting a 2- to 4-Week Ki67 Value > 10%
After Starting Aromatase Inhibition
Among the 49 patients whose week 2–Ki67 was . 10%, 35
patients switched to neoadjuvant chemotherapy; three patients
continued with AI, eight patients went directly to surgery, two
patients went to surgery after a rebiopsy at week 4 and again found
their Ki67 to be . 10%; one patient pursued treatment outside of
this study. Twenty-five (71.4%) of the 35 had an anthracycline-
containing regimen (Table 2). Six patients (17.1%) failed to
complete their planned course of chemotherapy because of in-
tolerability. There were two (5.7%; 95% CI, 0.7% to 19.1%) pCRs
among these 35 patients. A pCR occurred in a 55-year-old woman
with cT2N0 ductal breast cancer with a 2-week Ki67 of 80.0%
treated with doxorubicin and cyclophosphamide (AC) plus docetaxel.
The second pCR was in a 59-year-old woman with cT3N1 ductal
breast cancer with a 2-week Ki67 of 31.7% subsequently treated with
docetaxel plus gemcitabine plus bevacizumab followed by AC plus
bevacizumab.
Neoadjuvant Outcomes for ACOSOG Z1031B Patients
Whose Week 2 to 4 Ki67 Was £ 10%
There were 187 patients whose 2-week Ki67 value was
either # 10% (165) or not determined because of insufficient
tumor in the biopsy specimen (22). One of 187 patients whose
week 2–Ki67 value was # 10% chose to go directly to surgery
rather than continue on AI. Of 22 patients whose 2-week Ki67
value was not obtained, all chose to remain on AI either after
a rebiopsy at week 4 Ki67 of# 10% (six patients) or after forgoing
a rebiopsy at 4 weeks (16 patients; see Fig 1 for exact disposition
of all patients). Among the remaining 177 patients, pathologic
evaluation revealed no residual disease in the breast or lymph
nodes in three patients, in only the breast in 92 patients, and in
both the breast and lymph nodes in 82 patients (Table 3). The pCR
rate among the 186 women who completed AI was therefore 1.6%
(95%CI, 0.3% to 4.6%). PEPI scores were: 0 in 64 patients; 1 to 7 in
109 patients; and not determined in 13 patients because of pro-
gression during neoadjuvant AI therapy (two patients), lack of Allred
score or Ki67 from surgical specimen (four patients), or failure to
undergo surgery for reasons other than progression (seven patients).
Thus, the PEPI-0 rate was 34.4% (95% CI, 27.6% to 41.7%).
Registration
(N = 245)
Breast biopsy after 2 weeks of NET
(n = 236)
Unable to ascertain Ki67 as
no invasive tumor in
biopsy specimen
(n = 22)
Ki67 ≤ 10%
(n = 165)
Ki67 > 10%
(n = 49)
Continue AI,
no week-4
biopsy
(n = 16)
Continue AI,
week-4 Ki67
≤ 10% so
continued AI
(n = 6)
Continue AI
(n = 164)
Surgery
(n = 1)
Chose to
continue AI
(n = 3)
Continued
AI, week-4
Ki67 also
>10%, chose
surgery
(n = 2)
Surgery
(n = 8)
Off study
(n = 1)
Switched to
NAC
(n = 35)
Cancelled participation before start of treatment
Ineligible because receiving treatment for cervical cancer
Bilateral disease
(n = 3)
(n = 1)
(n = 2)
Withdrew consent before week-2 biopsy
Discontinued because of intolerability before week-2 biopsy
(n = 2)
(n = 1)
Fig 1. CONSORT diagram for the ACOSOG Z1031B patients. AI, aromatase inhibitor; Ki67, protein encoded by theMKI67 gene; NAC, neoadjuvant chemotherapy; NET,
neoadjuvant endocrine therapy.
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Adjuvant Chemotherapy Decisions for Patients With
a PEPI = 0
Management without adjuvant chemotherapy was the pre-
ferred protocol approach for patients in the PEPI = 0 category.
This occurred in 57 of 64 PEPI = 0 patients (89%). In contrast,
45 (41.2%) of 109 patients with a PEPI . 0 received adjuvant
chemotherapy.
Long-Term Outcomes for ACOSOG Z1031 Patients
According to PEPI Status
Clinical outcomes after surgery were examined in 287
ACOSOG Z1031A patients and 173 ACOSOG Z1031B patients
who completed neoadjuvant AI (REMARK, Fig 2). Overall, 119
(25.9%) tumors were categorized as PEPI = 0. Adjuvant che-
motherapy was administered in 18 (15.1%) of 119 PEPI = 0 cases
and 162 (47.5%) of 341 PEPI. 0 patients. Adjuvant radiation was
administered in 80 (67.2%) of 119 PEPI = 0 cases and 242 (71.0%)
of 341 PEPI. 0 cases. At data lock, all patients have been followed
until death or a median of 5.5 years postsurgery, with 365 patients
alive without a disease progression, 21 alive with disease re-
currence, 32 dead after disease recurrences, and 42 patients dead as
a result of a second cancer (six patients), noncancer causes (28
patients), or unknown causes (eight patients). A total of 49 patients
with PEPI . 0 disease experienced recurrence: local (seven), re-
gional (two), distant (39), and locoregional/distant (one); and four
patients with PEPI = 0 disease experienced recurrence (all distant).
The hazard of breast cancer recurrence for PEPI = 0 cases relative
to the PEPI . 0 cases was 0.27 (P = .014; 95% CI, 0.092 to 0.764)
when stratifying by cohort and known adjuvant chemotherapy use.
Kaplan-Meier plots of the time to breast cancer recurrence by PEPI =
0 versus PEPI. 0 status are presented in Figure 3A for the combined
cohort and in Figure 3B for those patients who did not receive ad-
juvant chemotherapy. Because the Ki67 assay approach in ACOSOG
Z1031A is being tested prospectively in the ALTERNATE (Alternate
Approaches for Clinical Stage II or III Estrogen Receptor Positive
Breast Cancer Neoadjuvant Treatment in Postmenopausal Women:
A Phase III Study) trial, the PEPI-0 outcome for the ACOSOG
Z1031A cohort is shown separately (Fig 3C).
Prognosis for ACOSOG Z1031B Patients According to
Ki67 at 2 to 4 Weeks
The 35 patients who were triaged to chemotherapy have been
followed at least 1 year postsurgery or to death. At the time of the
data lock, there were 24 patients alive without a disease pro-
gression, six were alive with disease progression, two had died of
breast cancer, and three had died as a result of noncancer causes.
With a median follow-up of 4.4 years post registration, the risk of
relapse was increased for those with 2- to 4-week Ki67. 10% (log
rank P = .004; Fig 3D).
Table 2. Chemotherapy Approaches and Surgical Outcomes Among Patients
With a Week 2 Ki67 of . 10%Who Switched to Neoadjuvant Chemotherapy
Chemotherapy Approach or Surgical Outcome (n = 35)
Neoadjuvant chemotherapy regimen
AC 1 (2.9)
AC then paclitaxel or NAB-paclitaxel 10 (28.6)
ACT 3 (8.3)
TC with or without trastuzumab 7 (20.0)
FEC then docetaxel 4 (11.3)
FEC then paclitaxel 3 (8.3)
Paclitaxel then FAC 2 (5.7)
Paclitaxel then FEC 2 (5.7)
Ixabepilone/cyclophosphamide 1 (2.9)
Docetaxel plus carboplatin plus trastuzumab 1 (2.9)
Docetaxel plus gemcitabine plus bevacizumab,
then AC plus bevacizumab
1 (2.9)
Extent of breast surgery
Breast-conserving surgery 14 (40.0)
Modified radical mastectomy 21 (60.0)
Extent of nodal surgery
SLN procedure 11 (31.4)
ALND 15 (42.9)
SLN plus ALND 9 (25.7)
Residual disease in the breast
None 2 (5.7)
0.1-2.0 cm 16 (45.7)
2.1-5.0 cm 12 (34.3)
. 5.0 cm 5 (14.2)
No. of positive lymph nodes
Only fatty tissue identified in ALND specimen 1 (2.9)
0 19 (55.9)
1-3 11 (31.4)
4-9 4 (11.3)
NOTE. Data presented as No. (%).
Abbreviations: AC, doxorubicin and cyclophosphamide; ACT, doxorubicin, cy-
clophosphamide followed by paclitaxel; ALND, axillary lymph node dissection;
FAC, fluorouracil, doxorubicin, and cyclophosphamide; FEC, fluorouracil, epi-
rubicin, and cyclophosphamide; NAB, paclitaxel, nanoparticle albumin-bound
paclitaxel; SLN, sentinel lymph node; TC, docetaxel, cyclophosphamide.
Table 3. Outcomes Among Patients With Week 2 Ki67 of # 10% or Not
Determined Who Continued on Neoadjuvant Aromatase Inhibitor
Outcome (n = 186)
Breast surgery preformed
None 9 (4.8)
Breast-conserving surgery 115 (61.8)
Modified radical mastectomy 62 (33.3)
Nodal surgery performed
No nodal evaluation 10 (5.4)
SLN procedure 114 (61.3)
ALND 38 (20.4)
SLN plus ALND 24 (12.9)
Residual breast disease (found on pathologic examination)
None 3 (1.6)
0.1-2.0 cm 73 (39.2)
2.1-5.0 cm 85 (45.7)
. 5.0 cm 16 (8.6)
Not applicable 9 (4.8)
No. of positive lymph nodes (found on pathologic examination)
Not examined 10 (5.4)
0 94 (50.5)
1-3 53 (28.5)
4-9 18 (9.7)
. 10 11 (5.9)
PEPI score
0 64 (34.4)
1-7 109 (58.6)
Nonzero 2 (1.1)
Not determinable 11 (5.9)
NOTE. Data presented as No. (%).
Abbreviations: ALND, axillary lymph node dissection; Ki67, protein encoded by
the MKI67 gene; PEPI, Preoperative Endocrine Prognostic Index; SLN, sentinel
lymph node.
jco.org © 2017 by American Society of Clinical Oncology 1065
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Gene Expression Analysis and Treatment-Induced
Tumor Proliferation Status
The low pCR rate to chemotherapy in ACOSOG Z1031B
prompted a further investigation of tumor proliferation status.
Paired high tumor content frozen tumor samples before and
after 2 or 4 weeks of AI were available in 109 of the 245 patients
and were used for mRNA expression profiling (REMARK, Fig
4A). Proliferation status was determined using a noncom-
mercial MGPS.14 Pairwise analysis demonstrated mRNA levels
for ER, progesterone receptor, and Ki67, and MGPS values
were markedly suppressed with treatment (Wilcoxon signed
rank P . .001). Box plots comparing the MGPS scores at
baseline and 2 weeks are illustrated in Figure 4C. The MGPS
scores were higher at both baseline and after 2 weeks in the
Z1031A cohort
(N = 377)
Surgery after completion of AI
(n = 337)
Long-term analysis cohort
(n = 287)
Exclusions
    Withdrew consent; did not start NET
    Extensive bone metastases or bilateral invasive breast
     disease found at registration
    Disease progression or second primary disease found
     during NET
    Refused to continue NET or undergo surgery
    Alternative therapy administered before surgery
    Surgery counter indicated due to comorbid conditions
(n = 3)
(n = 3)
(n = 17)
(n = 13)
(n = 1)
(n = 3)
Exclusions
    Central laboratory test of Ki67 and Allred score not
     performed
    One or more of PEPI-score elements missing;
      unable to determine whether score was zero or
      non-zero
(n = 37)
(n = 13)
A
Z1031B cohort
(N = 245) 
Surgery after completion of AI
(n = 177)
Long-term analysis cohort
(n = 173)
Cancelled participation before start of treatment
Ineligible because receiving treatment for cervical cancer
Bilateral disease
Withdrew consent before week-2 biopsy
Discontinued due to intolerability before week-2 biopsy
Two to 4-week Ki67 > 10%
Refused to continue on AI after 2 to 4-week Ki67 ≤ 10%
Refused to undergo surgery
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Fig 2. REMARK diagrams for the long-
term outcome analysis by Preoperative
Endocrine Therapy Prognostic Index (PEPI)
score for (A) ACOSOG Z1031A patients, and
(B) ACOSOG Z1031B patients. AI, aroma-
tase inhibitor; Ki67, protein encoded by the
MKI67 gene; NET, neoadjuvant endocrine
therapy.
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cohort, with 2-week Ki67 values of . 10% compared with
# 10% (Fig 4C; P , .001). The Spearman correlation coefficient
at 2 to 4 weeks between Ki67 values and the MGPS was 0.49
(Fig 4D).
DISCUSSION
The PEPI is a distinct prognostic approach for ER-positive breast
cancer that depends on tumor features after neoadjuvant endo-
crine therapy. PEPI integrates residual disease burden and the cell
cycle (Ki67) response providing a simple approach to deescalating
adjuvant treatment after neoadjuvant AI for patients in the PEPI =
0 category. These patients, who had a risk of relapse of 3% with
a median follow-up of approximately 5 years, are therefore unlikely
to benefit from adjuvant chemotherapy. Aweakness of the study is
that the relapse risk estimate is based on only 119 cases; thus, PEPI
validation efforts should continue.
Concerns regarding the variability in Ki67 analysis have been
discussed extensively.15 The imaging analysis approach to Ki67
estimation used for the ACOSOG Z1031A cohort is promising (Fig
3C), but conclusive data using this methodology await the results of
the ALTERNATE trial.
The low pCR rate for ACOSOG Z1031B patients who
switched to neoadjuvant chemotherapy contradicts the hy-
pothesis that AI-resistant proliferation in ER-rich tumors is
associated with enhanced chemotherapy response. The muted
chemotherapy response was unlikely because of the Ki67 assay
failure to capture highly proliferative tumors, because an
independent examination of tumor cell cycle activity with
a multigene proliferation score indicated significantly higher
expression of cell cycle–dependent genes when the Ki67 was
. 10% at 2 to 4 weeks (Figs 4C and 4D). Low chemotherapy
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Fig 3. Kaplan-Meier analysis by Preoperative Endocrine Prognostic Index (PEPI) = 0 (pathologic stage II or IIA, surgical specimen protein encoded by the MKI67 gene
(Ki67), 2.7%, and estrogen receptor Allred score. 2) versus PEPI. 0 (A) for all patients, (B) for patientswho did not receive adjuvant chemotherapy, and (C) for patients in
the ACOSOG Z1031A cohort alone. (D) Outcomes for patients according to the 10% Ki67 cut point on ACOSOG Z1031B.
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responsiveness could reflect the postmenopausal status of the
patient cohort,16 the high ER content of tumors eligible for
neoadjuvant endocrine therapy,17,18 or the use of endocrine
therapy before neoadjuvant chemotherapy. However, the
latter hypothesis seems unlikely because, unlike prior studies
that raised this concern,19 endocrine therapy was not ad-
ministered concurrently with chemotherapy.
Our data provide further support for an assessment of
prognosis in ER-positive breast cancer on the basis of post–
neoadjuvant endocrine therapy tumor characteristics. Triaging
patients to neoadjuvant chemotherapy on the basis of failure to
suppress Ki67 is feasible but highlights the relative chemotherapy-
resistant nature of strongly ER-positive yet AI-resistant disease in
postmenopausal women and the early relapse risk faced by patients
in this category in all three studies where this question can be
examined (Fig 3D; Data Supplement). The development of new
treatment options for intrinsically AI-resistant disease will likely
depend on new insights into the molecular basis for primary
endocrine therapy resistance.20,21
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Appendix
Table A1. Early Ki67 Assessments and Outcome in IMPACT and POL Trials
Trial PEPI-0 (%) RFS (%)
POL 4W Ki67, 95-month median follow-up
. 10% 1 of 19 (5) 8 of 21 (38)
# 10% 10 of 36 (28) 5 of 41(12)
P value .08 (Fisher’s exact test) .0016 (log-rank test)
IMPACT trial, 37-month median follow-up
. 10% 0 of 32(0) 9 of 35(26)
# 10% 21 of 101(21) 13 of 118 (11)
P value .004 (Fisher’s exact test) .008 (log-rank test)
Abbreviations: 4WKi67, Ki67 value after 4weeks of AI treatment; IMPACT, Immediate Preoperative Anastrozole, Tamoxifen, or Combinedwith Tamoxifen; Ki67, protein
encoded by the MKI67 gene; PEPI, Preoperative Endocrine Prognostic Index; POL, Preoperative Letrozole trial; RFS, relapse-free survival.
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Fig A1. Relapse patterns in the two independent training sets used to justify the 10% early on treatment cut point for triage to chemotherapy in Z1031B. (A) is based on
data from the IMPACT trial10 and (B) from data derived from the Preoperative Letrozole (POL) Trial9. In both studies, on-treatment Ki67 values of.10% identified in a biopsy
taken at 2 weeks (IMPACT) or 4 weeks (POL) are associated with a significantly higher risk of subsequent relapse over time than patients with values of#10% at the same
time point.
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